Metastatic prostate cancer develops when cancer cells spread beyond the prostate to other parts of the body. The bones and lymph nodes are common sites, although the disease can also affect other organs.
Treatment has changed considerably over the past two decades. Alongside conventional androgen deprivation therapy, patients may now receive medicines that suppress androgen production more extensively. Abiraterone acetate is one of the established treatments that has helped expand options for certain patients with metastatic prostate cancer.
Abiraterone acetate is not a cure, and it is not suitable for every patient. However, clinical studies have shown that it can delay disease progression and improve survival in specific treatment settings when used as part of a carefully managed treatment plan.
| Treatment feature | Details | Why it matters |
|---|---|---|
| Medicine class | Androgen biosynthesis inhibitor | Reduces hormones that can encourage prostate cancer growth |
| Main molecular target | CYP17 enzyme | Blocks a key step involved in androgen production |
| Treatment form | Oral tablets | Can usually be taken at home according to a prescribed schedule |
| Main use | Certain types of metastatic prostate cancer | May be used in hormone-sensitive or castration-resistant disease |
| Companion medicine | Usually prednisone or prednisolone | Helps manage hormonal changes and reduce specific complications |
| Additional therapy | Androgen deprivation therapy may continue | Maintains low testosterone levels throughout treatment |
| Treatment goal | Slow cancer progression and extend disease control | May improve outcomes but does not guarantee a cure |
| Monitoring | PSA, liver function, potassium and blood pressure | Helps assess response and identify side effects early |
Prostate cancer cells often depend on androgens to grow. Traditional androgen deprivation therapy lowers testosterone produced by the testicles, but smaller amounts of androgens can still be produced by the adrenal glands and within prostate cancer tissue.
Abiraterone inhibits CYP17, an enzyme needed for androgen production. This reduces androgen levels more extensively than conventional androgen deprivation therapy alone.
By limiting the hormonal signals available to cancer cells, abiraterone may:
The response varies between individuals. Some patients experience prolonged disease control, while others may develop resistance or require a different treatment.
Abiraterone acetate is used in specific metastatic prostate cancer settings. A cancer specialist will consider the stage of the disease, previous treatment, general health and potential risks before recommending it.
Castration-sensitive prostate cancer continues to respond when testosterone levels are reduced.
Abiraterone may be added to standard androgen deprivation therapy for patients with metastatic high-risk castration-sensitive prostate cancer. Starting a more intensive treatment combination earlier may help delay progression in suitable patients.
Castration-resistant prostate cancer continues to grow even though testosterone has been reduced to very low levels through treatment or surgery.
The cancer may still depend on small amounts of androgen produced outside the testicles. Abiraterone can further suppress androgen production and may remain effective even after standard hormone therapy has stopped controlling the disease.
The approved treatment settings include metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer when used with prednisone.
Abiraterone has become important because it targets androgen production through a different mechanism from conventional hormone therapy.
Clinical trials involving patients with metastatic prostate cancer found that treatment with abiraterone and prednisone improved overall survival compared with prednisone and placebo in the populations studied. Benefits were demonstrated in previously treated metastatic castration-resistant disease, chemotherapy-naive metastatic castration-resistant disease and high-risk metastatic castration-sensitive disease. The potential benefits may include:
These results describe groups of patients in clinical trials. They cannot predict exactly how long an individual patient will respond.
Blocking CYP17 changes the body’s production of several steroid hormones. This can lead to excess mineralocorticoid activity, which may cause high blood pressure, low potassium and fluid retention.
Prednisone or prednisolone helps compensate for the reduction in natural corticosteroid production and lowers the risk of these complications.
Patients should not reduce or stop their prescribed corticosteroid suddenly unless instructed by their healthcare team. Abrupt interruption may contribute to adrenal insufficiency, particularly during illness, infection, surgery or other physical stress.
Abiraterone acetate should be taken exactly as prescribed. The dose, companion corticosteroid and administration instructions can depend on the product formulation and treatment setting.
For conventional abiraterone acetate tablets, patients are generally instructed to:
Abiraterone begins affecting androgen production after treatment starts, but patients may not immediately notice a physical change.
A fall in PSA may be one indication of response, although PSA should not be interpreted alone. Some patients may have stable symptoms before a clear change is seen on scans.
Doctors normally evaluate treatment over a series of appointments using:
There is no universal response timeline. Treatment should not be considered ineffective solely because symptoms or PSA do not improve immediately.
Regular monitoring helps determine whether the cancer is responding and whether the medicine is being tolerated safely.
| Test or assessment | Purpose | Possible action if concerns arise |
|---|---|---|
| PSA test | Tracks changes in prostate cancer activity | Further tests may be arranged if PSA rises consistently |
| Testosterone level | Confirms that androgen suppression remains adequate | Hormonal treatment may be reviewed |
| Liver function tests | Detect possible liver injury | Treatment may be interrupted, reduced or discontinued |
| Blood potassium test | Identifies low potassium | Potassium may be corrected and treatment reassessed |
| Blood pressure check | Detects new or worsening hypertension | Blood pressure treatment may be started or adjusted |
| Weight and swelling assessment | Helps identify fluid retention | Additional investigation or treatment may be required |
| Blood glucose test | Monitors patients with diabetes or glucose-related risks | Diabetes medicines may need review |
| Imaging scans | Assesses tumours and metastatic disease | The treatment plan may change if progression is confirmed |
| Symptom review | Evaluates pain, fatigue, weakness and general well-being | Supportive care or further testing may be recommended |
| Cardiac assessment | Evaluates patients with cardiovascular risk factors | Closer monitoring or an alternative treatment may be considered |
Before treatment begins, patients should tell their healthcare team if they have:
Abiraterone can affect the way certain medicines are processed. Other medicines may also change the amount of abiraterone in the bloodstream. Potentially important interactions include:
Abiraterone with prednisone or prednisolone is not recommended in combination with radium-223 outside clinical trials because an increased risk of fractures and death was observed with concurrent use.
Patients should not start, stop or change another medicine without consulting the clinician managing their cancer treatment.
| Feature | Abiraterone acetate | Chemotherapy |
|---|---|---|
| Treatment type | Targeted hormonal therapy | Cytotoxic cancer treatment |
| Main action | Reduces androgen production | Damages or prevents the division of cancer cells |
| Administration | Oral tablets | Usually intravenous infusion |
| Treatment location | Usually taken at home | Commonly administered at a clinic or hospital |
| Common monitoring | PSA, liver function, potassium and blood pressure | Blood counts, organ function and infection risk |
| Typical side-effect focus | Hypertension, low potassium, swelling and liver changes | Low blood counts, infection, hair loss, nausea and neuropathy |
| Role in care | May be used in hormone-sensitive or castration-resistant disease | May be used at different stages depending on disease features |
| Treatment choice | Based on cancer status and individual health | Based on cancer burden, symptoms, fitness and previous therapy |
One treatment is not automatically better than the other. Some patients may receive both at different stages, while others may be better suited to one approach.
Doctors look at the overall pattern rather than relying on a single result. Possible signs of benefit may include:
There is no fixed treatment duration for every patient. Treatment may continue while:
A doctor may temporarily interrupt treatment, reduce the dose or discontinue the medicine if significant toxicity develops. Patients should never change the dose independently.
Medical treatment remains the priority, but daily habits can support general well-being. Patients may be advised to:
Supplements and herbal products should only be used after medical review because some may interact with cancer treatment.
Medical disclaimer:
This content is provided for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Abiraterone acetate is a prescription medicine and must be used only under the supervision of a qualified healthcare professional.
